Ultimovacs ASA Ownership
| ULTI Stock | NOK 2.07 0.02 0.98% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Ultimovacs |
Ultimovacs Stock Ownership Analysis
About 48.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 5.09. Ultimovacs ASA had not issued any dividends in recent years. Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company was incorporated in 2011 and is headquartered in Oslo, Norway. ULTIMOVACS ASA is traded on Oslo Stock Exchange in Norway. For more information please call the company at 47 41 38 00 80 or visit https://ultimovacs.com.Ultimovacs ASA Outstanding Bonds
Ultimovacs ASA issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ultimovacs ASA uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ultimovacs bonds can be classified according to their maturity, which is the date when Ultimovacs ASA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.